Search

We examine the effect of growth temperature in the 150−300 °C range on the structural and morphological properties of Al2O3films deposited using atomic layer deposition, contrasting the effect of H2O and O3as oxygen sources. Trimethylaluminum (TMA) is the metal source. A mechanism for the O3reaction is investigated using ab initio calculations and provides an explanation for the observed temperature dependence. The simulations show that hydroxyl groups are produced at the surface by the oxidation of adsorbed methyl groups by O3. This is confirmed by the measured rates; both H2O and O3processes show molar growth rates per cycle that decrease with increasing reactor temperature, consistent with a decrease in hydroxyl coverage. At no temperature does the O3process deposit more Al2O3per cycle than the H2O process. Morphological characterization shows that O3as the oxygen source yields lower-quality films than H2O; the films are less dense and rougher, especially at low growth temperatures. The existence of voids correlates with the low film electronic density. This may indicate the low mobility of surface hydroxyl at low temperatures, an effect that is washed out by repeated exchange with the vapor phase in the H2O case.

Density functional calculations have been performed to study the structure and energetics of mainly neutral Aln with n up to 153. Clusters up to n=15 have been investigated systematically, in part by simulated annealing techniques. No pronounced islands of stability are found in this range although Al7 and Al13 are of special importance. The treatment of selected larger clusters with different packings and cluster shapes leads to the following conclusions. Icosahedral packing is favoured only for n=13; around n=55, decahedral packing is most stable, whereas fcc is definitely preferred, energetically, for n>80. Among clusters of comparable size and packing those with dominantly (111) surfaces are found to be most stable. These trends are rationalized by considering the average number of next neighbours and the internal strain arising from a mismatch of bond distances. Extrapolation of the computed cluster binding energies yields a cohesive energy of bulk Al of 3.3–3.4 eV, in close agreement with experiment (3.36 eV).

The present study describes the pharmacological profile of ((E)-alpha-[[1-butyl-5-[2-[(2-carboxyphenyl)methoxy]-4-methoxy-phenyl ]-1H-pyrazol-4-yl]methlene]-6-methoxy-1,3-benzodioxole-5-propanoic acid) (SB 234551), a high-affinity, nonpeptide endothelin type A (ETA)-selective receptor antagonist. In human cloned ETA and endothelin type B (ETB) receptors, SB 234551 produced a concentration-dependent displacement of [125I]-endothelin-1 with Ki values of 0.13 and 500 nM, respectively. SB 234551 elicited concentration-dependent, rightward competitive shifts in the endothelin-1 concentration-response curves in isolated rat aorta and isolated human pulmonary artery (ETA receptor-mediated vascular contraction) with Kb values of 1.9 and 1.0 nM, respectively. SB 234551 antagonized ETB receptor-mediated vasoconstriction in the isolated rabbit pulmonary artery, as demonstrated by concentration-dependent, rightward shifts in the sarafotoxin S6c concentration-response curves (Kb = 555 nM). SB 234551 produced weak functional inhibition of sarafotoxin S6c-mediated endothelium-dependent relaxation (IC50 = 7 microM). SB 234551 (10 microM) had no significant effect against contraction produced by several other vasoactive agents and did not significantly influence radioligand binding to a number of diverse receptors. SB 234551 (0. 1-1.0 mg/kg i.v.) dose-dependently inhibited the pressor response to exogenous endothelin-1 in conscious rats. In vivo pharmacokinetic analysis in the rat demonstrated that SB 234551 was rapidly absorbed from the GI tract with a bioavailability of 30%. SB 234551 had a plasma half-life of 125 min and a systemic clearance of 25.0 ml/min/kg. The present study demonstrates that SB 234551 is an antagonist with high affinity for the ETA receptor, while sparing the ETB receptor. SB 234551 is a new pharmacological tool that should assist in the elucidation of the role of endothelin in pathophysiology.